Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

GRDN vs CVS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
GRDN
Guardian Pharmacy Services, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$2.32B
5Y Perf.+117.7%
CVS
CVS Health Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$111.32B
5Y Perf.+38.1%

GRDN vs CVS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
GRDN logoGRDN
CVS logoCVS
IndustryMedical - DistributionMedical - Healthcare Plans
Market Cap$2.32B$111.32B
Revenue (TTM)$1.46B$407.90B
Net Income (TTM)$53M$2.93B
Gross Margin20.2%13.9%
Operating Margin6.4%1.5%
Forward P/E29.9x12.1x
Total Debt$45M$93.59B
Cash & Equiv.$66M$8.51B

GRDN vs CVSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

GRDN
CVS
StockSep 24May 26Return
Guardian Pharmacy S… (GRDN)100217.7+117.7%
CVS Health Corporat… (CVS)100138.1+38.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: GRDN vs CVS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: GRDN leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. CVS Health Corporation is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
GRDN
Guardian Pharmacy Services, Inc.
The Income Pick

GRDN carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 0 yrs, beta 1.04
  • Rev growth 17.9%, EPS growth 144.1%, 3Y rev CAGR 16.8%
  • 128.6% 10Y total return vs CVS's 3.9%
Best for: income & stability and growth exposure
CVS
CVS Health Corporation
The Insurance Pick

CVS is the clearest fit if your priority is defensive.

  • Beta 0.05, yield 3.1%, current ratio 0.84x
  • Lower P/E (12.1x vs 29.9x)
  • Beta 0.05 vs GRDN's 1.04
Best for: defensive
See the full category breakdown
CategoryWinnerWhy
GrowthGRDN logoGRDN17.9% revenue growth vs CVS's 7.8%
ValueCVS logoCVSLower P/E (12.1x vs 29.9x)
Quality / MarginsGRDN logoGRDN3.6% margin vs CVS's 0.7%
Stability / SafetyCVS logoCVSBeta 0.05 vs GRDN's 1.04
DividendsCVS logoCVS3.1% yield; the other pay no meaningful dividend
Momentum (1Y)GRDN logoGRDN+42.3% vs CVS's +35.2%
Efficiency (ROA)GRDN logoGRDN13.4% ROA vs CVS's 1.1%, ROIC 35.1% vs 5.0%

GRDN vs CVS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

GRDNGuardian Pharmacy Services, Inc.
FY 2025
Corporate Segment
100.0%$1.4B
CVSCVS Health Corporation
FY 2025
Pharmacy Revenue
58.9%$229.0B
Premiums
34.6%$134.8B
Front Store Revenue
5.5%$21.5B
Product and Service, Other
1.0%$3.9B

GRDN vs CVS — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLGRDNLAGGINGCVS

Income & Cash Flow (Last 12 Months)

GRDN leads this category, winning 4 of 6 comparable metrics.

CVS is the larger business by revenue, generating $407.9B annually — 280.2x GRDN's $1.5B. Profitability is closely matched — net margins range from 3.6% (GRDN) to 0.7% (CVS). On growth, CVS holds the edge at +6.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricGRDN logoGRDNGuardian Pharmacy…CVS logoCVSCVS Health Corpor…
RevenueTrailing 12 months$1.5B$407.9B
EBITDAEarnings before interest/tax$112M$9.4B
Net IncomeAfter-tax profit$53M$2.9B
Free Cash FlowCash after capex$70M$7.4B
Gross MarginGross profit ÷ Revenue+20.2%+13.9%
Operating MarginEBIT ÷ Revenue+6.4%+1.5%
Net MarginNet income ÷ Revenue+3.6%+0.7%
FCF MarginFCF ÷ Revenue+4.8%+1.8%
Rev. Growth (YoY)Latest quarter vs prior year+2.2%+6.2%
EPS Growth (YoY)Latest quarter vs prior year+40.0%+63.1%
GRDN leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

CVS leads this category, winning 5 of 6 comparable metrics.

At 46.9x trailing earnings, GRDN trades at a 25% valuation discount to CVS's 62.5x P/E. On an enterprise value basis, CVS's 13.1x EV/EBITDA is more attractive than GRDN's 20.6x.

MetricGRDN logoGRDNGuardian Pharmacy…CVS logoCVSCVS Health Corpor…
Market CapShares × price$2.3B$111.3B
Enterprise ValueMkt cap + debt − cash$2.3B$196.4B
Trailing P/EPrice ÷ TTM EPS46.90x62.49x
Forward P/EPrice ÷ next-FY EPS est.29.86x12.13x
PEG RatioP/E ÷ EPS growth rate2.50x
EV / EBITDAEnterprise value multiple20.64x13.10x
Price / SalesMarket cap ÷ Revenue1.60x0.28x
Price / BookPrice ÷ Book value/share10.62x1.46x
Price / FCFMarket cap ÷ FCF28.71x14.26x
CVS leads this category, winning 5 of 6 comparable metrics.

Profitability & Efficiency

GRDN leads this category, winning 9 of 9 comparable metrics.

GRDN delivers a 25.4% return on equity — every $100 of shareholder capital generates $25 in annual profit, vs $4 for CVS. GRDN carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), GRDN scores 6/9 vs CVS's 5/9, reflecting solid financial health.

MetricGRDN logoGRDNGuardian Pharmacy…CVS logoCVSCVS Health Corpor…
ROE (TTM)Return on equity+25.4%+3.9%
ROA (TTM)Return on assets+13.4%+1.1%
ROICReturn on invested capital+35.1%+5.0%
ROCEReturn on capital employed+41.5%+6.1%
Piotroski ScoreFundamental quality 0–965
Debt / EquityFinancial leverage0.21x1.24x
Net DebtTotal debt minus cash-$21M$85.1B
Cash & Equiv.Liquid assets$66M$8.5B
Total DebtShort + long-term debt$45M$93.6B
Interest CoverageEBIT ÷ Interest expense101.92x4.19x
GRDN leads this category, winning 9 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

GRDN leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in GRDN five years ago would be worth $22,862 today (with dividends reinvested), compared to $11,843 for CVS. Over the past 12 months, GRDN leads with a +42.3% total return vs CVS's +35.2%. The 3-year compound annual growth rate (CAGR) favors GRDN at 31.7% vs CVS's 10.8% — a key indicator of consistent wealth creation.

MetricGRDN logoGRDNGuardian Pharmacy…CVS logoCVSCVS Health Corpor…
YTD ReturnYear-to-date+23.9%+10.1%
1-Year ReturnPast 12 months+42.3%+35.2%
3-Year ReturnCumulative with dividends+128.6%+35.9%
5-Year ReturnCumulative with dividends+128.6%+18.4%
10-Year ReturnCumulative with dividends+128.6%+3.9%
CAGR (3Y)Annualised 3-year return+31.7%+10.8%
GRDN leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

CVS leads this category, winning 2 of 2 comparable metrics.

CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than GRDN's 1.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.0% from its 52-week high vs GRDN's 88.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricGRDN logoGRDNGuardian Pharmacy…CVS logoCVSCVS Health Corpor…
Beta (5Y)Sensitivity to S&P 5001.04x0.05x
52-Week HighHighest price in past year$41.36$88.63
52-Week LowLowest price in past year$19.17$58.35
% of 52W HighCurrent price vs 52-week peak+88.4%+98.0%
RSI (14)Momentum oscillator 0–10051.357.1
Avg Volume (50D)Average daily shares traded443K7.4M
CVS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates GRDN as "Buy" and CVS as "Buy". Consensus price targets imply 9.6% upside for CVS (target: $95) vs 3.9% for GRDN (target: $38). CVS is the only dividend payer here at 3.08% yield — a key consideration for income-focused portfolios.

MetricGRDN logoGRDNGuardian Pharmacy…CVS logoCVSCVS Health Corpor…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$38.00$95.20
# AnalystsCovering analysts341
Dividend YieldAnnual dividend ÷ price+3.1%
Dividend StreakConsecutive years of raises00
Dividend / ShareAnnual DPS$2.67
Buyback YieldShare repurchases ÷ mkt cap+1.3%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

GRDN leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CVS leads in 2 (Valuation Metrics, Risk & Volatility).

Best OverallGuardian Pharmacy Services,… (GRDN)Leads 3 of 6 categories
Loading custom metrics...

GRDN vs CVS: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is GRDN or CVS a better buy right now?

For growth investors, Guardian Pharmacy Services, Inc.

(GRDN) is the stronger pick with 17. 9% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). Guardian Pharmacy Services, Inc. (GRDN) offers the better valuation at 46. 9x trailing P/E (29. 9x forward), making it the more compelling value choice. Analysts rate Guardian Pharmacy Services, Inc. (GRDN) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — GRDN or CVS?

On trailing P/E, Guardian Pharmacy Services, Inc.

(GRDN) is the cheapest at 46. 9x versus CVS Health Corporation at 62. 5x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 1x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — GRDN or CVS?

Over the past 5 years, Guardian Pharmacy Services, Inc.

(GRDN) delivered a total return of +128. 6%, compared to +18. 4% for CVS Health Corporation (CVS). Over 10 years, the gap is even starker: GRDN returned +128. 6% versus CVS's +3. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — GRDN or CVS?

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

05β versus Guardian Pharmacy Services, Inc. 's 1. 04β — meaning GRDN is approximately 1956% more volatile than CVS relative to the S&P 500. On balance sheet safety, Guardian Pharmacy Services, Inc. (GRDN) carries a lower debt/equity ratio of 21% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — GRDN or CVS?

By revenue growth (latest reported year), Guardian Pharmacy Services, Inc.

(GRDN) is pulling ahead at 17. 9% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Guardian Pharmacy Services, Inc. grew EPS 144. 1% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, GRDN leads at 16. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — GRDN or CVS?

Guardian Pharmacy Services, Inc.

(GRDN) is the more profitable company, earning 3. 4% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 3. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GRDN leads at 6. 1% versus 2. 6% for CVS. At the gross margin level — before operating expenses — GRDN leads at 19. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is GRDN or CVS more undervalued right now?

On forward earnings alone, CVS Health Corporation (CVS) trades at 12.

1x forward P/E versus 29. 9x for Guardian Pharmacy Services, Inc. — 17. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CVS: 9. 6% to $95. 20.

08

Which pays a better dividend — GRDN or CVS?

In this comparison, CVS (3.

1% yield) pays a dividend. GRDN does not pay a meaningful dividend and should not be held primarily for income.

09

Is GRDN or CVS better for a retirement portfolio?

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), 3. 1% yield). Both have compounded well over 10 years (CVS: +3. 9%, GRDN: +128. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between GRDN and CVS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GRDN is a small-cap high-growth stock; CVS is a mid-cap income-oriented stock. CVS pays a dividend while GRDN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

GRDN

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 12%
Run This Screen
Stocks Like

CVS

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 1.2%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform GRDN and CVS on the metrics below

Revenue Growth>
%
(GRDN: 2.2% · CVS: 6.2%)
P/E Ratio<
x
(GRDN: 46.9x · CVS: 62.5x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.